Code availability
Not applicable.
Availability of data
All data are available from the corresponding author.
References
Catalano A, Vita GL, Bellone F, Sframeli M, Distefano MG, La Rosa M, Gaudio A, Vita G, Morabito N, Messina S (2022) Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates. J Endocrinol Invest 45(3):517–525. https://doi.org/10.1007/s40618-021-01676-4
Finsterer J, Strobl W (2011) Orthopaedic abnormalities in primary myopathies. Acta Orthop Belg 77(5):563–582
Ponzetti M, Ucci A, Maurizi A, Giacchi L, Teti A, Rucci N (2022) Lipocalin 2 influences bone and muscle phenotype in the MDX mouse model of Duchenne muscular dystrophy. Int J Mol Sci 23(2):958. https://doi.org/10.3390/ijms23020958
Wada E, Hamano T, Matsui I, Yoshida M, Hayashi YK, Matsuda R (2019) Renal involvement in the pathogenesis of mineral and bone disorder in dystrophin-deficient mdx mouse. J Physiol Sci 69(4):661–671. https://doi.org/10.1007/s12576-019-00683-8
Funding
No funding was received.
Author information
Authors and Affiliations
Contributions
JF: design, literature search, discussion, first draft, critical comments, final approval, WS: literature search, discussion, critical comments, final approval.
Corresponding author
Ethics declarations
Conflict of interest
None.
Ethics approval
Was in accordance with ethical guidelines. The study was approved by the institutional review board.
Consent to participate
Was obtained from the patient.
Consent for publication
Was obtained from the patient.
Human participants and animals statement
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Finsterer, J., Strobl, W. Bone quality in Duchenne muscular dystrophy. J Endocrinol Invest 45, 1265–1266 (2022). https://doi.org/10.1007/s40618-022-01783-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-022-01783-w